C.R. Bard, Inc. lost its appeal of a jury’s $2 million verdict in Fourth Circuit appellate court on Thursday. The court found that the medical device manufacturer was, in fact, responsible for the injuries the plaintiff suffered after she was implanted with the company’s transvaginal mesh device. In the appeal, Bard claimed that the district court wrongly excluded evidence regarding the FDA’s approval of its product. The court decided that the approval of the product did not adequately represent its safety, only how well it matched something already on the market.
Last week, the Food and Drug Administration (FDA) reclassified transvaginal mesh products as class III or "high risk" medical devices. This fact alone doesn't mean much without some context, but don't worry, we'll touch on that soon.… More
Boston Scientific Corp. was hit with a $73.4 million verdict earlier this month after a jury found that the company's Obtryx transvaginal sling was defective and caused serious injuries.… More
The FDA has announced it will not be recalling or banning transvaginal mesh products – or at least not yet. What prompted this announcement?… More
This week, J&J agreed to pay out $4 million to settle Oregon's claims that subsidiary DePuy Orthopaedics made false claims when advertising and selling its now recalled… More
What's the best advice for companies facing legal action? Admit nothing and deny everything, apparently. Endo International Plc. has certainly taken that to heart – and yesterday's news… More
There are 44,020 reasons not to trust transvaginal mesh – that's the total number of cases filed against seven different manufacturers as of March 13, 2014.… More
ClassAction.org is a group of online professionals (designers, programmers and writers) with years of experience in the legal industry. We work closely with class action and mass tort attorneys across the country and help with investigations into corporate wrongdoing.